Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Short Interest Report for October

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totaling 109,110 shares, a decline of 35.4% from the September 30th total of 168,895 shares. Based on an average daily trading volume, of 97,400 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.7% of the company’s shares are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Marker Therapeutics stock. Concurrent Investment Advisors LLC bought a new position in Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned about 0.41% of Marker Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 22.39% of the company’s stock.

Wall Street Analyst Weigh In

MRKR has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a research report on Friday, August 21st. Weiss Ratings upgraded Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 19th. Finally, Zacks Research raised shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Marker Therapeutics Price Performance

NASDAQ MRKR opened at $0.98 on Monday. The company has a market capitalization of $16.34 million, a P/E ratio of -2.39 and a beta of 1.53. Marker Therapeutics has a 1-year low of $0.84 and a 1-year high of $2.46. The business has a 50 day moving average price of $1.14 and a 200 day moving average price of $1.37.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.16. On average, research analysts expect that Marker Therapeutics will post -0.64 earnings per share for the current fiscal year.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors.

The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.